Fura

Quick links to important sections

Fura

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fura

Property Description
Active Ingredient Nitrofural (Nitrofurazone)
Form Topical Solution, Ointment, Cream
Pharmacological Class Synthetic Nitrofuran Antibacterial Agent
Common Use Localized bacterial control on skin and surface tissues
Origin Synthetic Organic Compound

What Type of Medicine Is Fura and What is its Active Component?

Fura is a pharmaceutical preparation classified as a topical anti-infective agent whose single active component is Nitrofural, also known by the generic name Nitrofurazone. This medicine belongs to the distinct chemical class of Nitrofuran derivatives, defining it as a completely synthetic organic compound not derived from natural sources, which is confirmed by its structural record.

The composition of Nitrofural is recognized for its stability and its focused action against microbial life. As a single-ingredient product, Fura's identity is strictly tied to this unique structure, which provides the necessary basis for managing localized bacterial contamination where systemic absorption is negligible.


Pharmacological Class and Purpose: Is Fura an Antibacterial Agent?

Fura is formally classified as a potent, broad-spectrum bactericidal agent, meaning its general purpose is to actively kill the pathogenic bacteria present at the application site. The World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system places Nitrofural in the Antiseptics and Disinfectants group, underscoring its role as a targeted external agent for infection control.

The drug's core benefit is derived from its bactericidal mechanism, which involves disrupting the energy production and metabolic functions within the bacterial cell. This action contributes to its reliable function in controlling and reducing bacterial presence on damaged tissue, such as superficial abrasions or minor burns.


Fura's Common Forms and Administration Route

The medicine is manufactured exclusively for direct surface application, utilizing the topical route of administration. Fura is typically available in several common dosage forms, including a topical solution, ointment, and cream.

These preparations combine the active ingredient, Nitrofural, with a suitable base or vehicle, such as polyethylene glycol or an aqueous medium, to ensure optimal local drug concentration. This focused design ensures that the antibacterial effect is highly concentrated precisely where it is required on the tissue surface.

What side effects are possible with Fura?

Possible Side Effects and Safety Information

The safety profile of Fura is strictly defined by authoritative government regulatory documents, outlining adverse reactions by frequency, system, and seriousness.

Serious Adverse Reactions and Regulatory Warnings

Official regulatory sources, such as the U.S. Food and Drug Administration (FDA) label, include a Boxed Warning that highlights the risk of disabling and potentially permanent serious adverse effects. These effects may involve the tendons, muscles, joints, nerves (peripheral neuropathy), and the central nervous system.

Serious adverse reactions documented in regulatory documents include:

  • Musculoskeletal and Neurological: Tendinitis and tendon rupture; peripheral neuropathy (numbness, tingling); central nervous system effects (e.g., psychosis, suicidal thoughts, hallucinations, confusion, anxiety, insomnia).
  • Other Serious Events: Worsening of myasthenia gravis, prolongation of the QT interval, severe diarrhea (Clostridium difficile-associated diarrhea), and hypersensitivity reactions/anaphylaxis.

These serious effects may occur within hours to weeks after starting the medicine and may persist for months to years after discontinuation.

Adverse Reactions by Frequency

Adverse reactions are classified based on the frequency observed in clinical studies and post-marketing surveillance:

  • Common Reactions: These are side effects that occur frequently, such as nausea, diarrhea, headache, and dizziness.
  • Less Common Reactions: This category includes serious, low-frequency events that are listed when a strong causality is suspected.

Safety-Related Restrictions

The official label lists Contraindications (situations where the medicine must not be used) and specific Warnings for use in certain patient populations. For example, Fura is contraindicated in patients with a history of hypersensitivity to the drug. Regulatory documents also restrict the use of Fura for certain uncomplicated infections due to the risks of serious adverse effects.

Overdose and Emergency Response

The official regulatory profile for Fura (Nitrofural) indicates that the systemic absorption of the active ingredient is limited, and toxicity from its topical use is generally considered negligible. The product is explicitly documented as not significantly toxic in man by topical application; therefore, no acute systemic overdose symptoms are formally listed for this route.


Manifestation Official Regulatory Statement
Systemic Toxicity Negligible, with no documented systemic symptoms for topical application.
At-Risk Populations Caution is required for patients with known or suspected renal impairment. The excipients in some preparations may be absorbed through damaged skin and could increase the risk of progressive renal impairment.

When to Seek Immediate Medical Help

Urgent medical attention must be sought for incidents of accidental ingestion of the preparation or upon the development of any systemic symptoms or severe local reactions.

Official Management Actions

Management is focused on providing symptomatic and supportive treatment. Regulatory documentation confirms that no specific antidote is known for Nitrofural overdose. Treatment must be discontinued if significant local irritation or sensitization is observed.

Therapeutic Uses of Fura

The therapeutic focus of Fura (Nitrofural) is strictly centered on providing localized antibacterial support in various clinical and traumatic settings, applied to assist with the management of bacterial symptoms on compromised skin tissue. The medication is relevant for easing the overall symptom load associated with infection in severe injuries and surgical procedures.

Fura is commonly used across conditions presenting with localized bacterial infections such as pyodermas, infected dermatoses, minor traumatic wounds, second- and third-degree burn wounds, long-standing cutaneous ulcers, and is utilized for both donor and recipient sites in skin grafting. It helps address symptom clusters that may become disruptive by addressing the symptoms related to infectious processes.

The primary benefit is that it supports functional stability and contributes to improved day-to-day comfort during symptomatic periods, applied in contexts where potential bacterial contamination is a factor. The medication is commonly applied in clinical settings that involve acute or unstable symptom patterns where supportive symptom management is appropriate.

“The topical antibacterial agent plays a role in managing potential bacterial contamination.”

Quick Fact: Relief for Localized Infection Symptoms

Eligibility and Restrictions for Use

The eligibility for using Fura (Nitrofural) topical preparations is defined by official regulatory documentation, outlining who is permitted to use the medicine and who is officially restricted or contraindicated.

Contraindicated Populations

The medicine is contraindicated for patients with a known prior sensitization or hypersensitivity to Nitrofurazone or any component of its formulation. This is the sole absolute non-eligibility rule.

Age and Developmental Limitations

Use is officially established in adults. However, use in pediatric patients and older adults (geriatric) is subject to official limitations because specific comparative data in these age groups is not established. Safe use during pregnancy (classified as Pregnancy Category C) and lactation has not been established, leading to a regulatory recommendation against its routine use unless the therapeutic benefit is officially judged to outweigh the possible risk.

Condition-Based Restrictions

Regulators advise caution for patients with existing kidney function impairment (renal disease) when using the topical solution or soluble dressing. This restriction is due to concerns that vehicle ingredients may be absorbed and eliminated abnormally. Caution is also advised for patients with a history of hepatic impairment.

What should I know about interactions with other medicines?

The official regulatory documentation for the topical formulation of Fura (Nitrofural) does not list traditional drug-drug, drug-food, or herbal supplement interactions involving the active ingredient. The low systemic absorption of Nitrofural in topical application means no formal pharmacokinetic data (e.g., CYP enzyme inhibition) or pharmacodynamic interaction statements are included in the regulatory label.

The only official constraint documented is a high-level caution related to the product’s vehicle. Certain Fura formulations, such as the ointment and soluble dressing, contain Polyethylene Glycol (PEG), a substance that is readily absorbed through damaged skin.

Population-Specific Vehicle Interaction

Classification Basis Constraint/Risk
Exposure Risk Pharmacokinetic (Vehicle Absorption) Increased systemic exposure of the vehicle (PEG).
At-Risk Population Physiological Status Patients with impaired renal function or extensive cutaneous exposure (e.g., severe burns).

This pharmacokinetic interaction is important because the accumulated Polyethylene Glycol in renally impaired patients may not be cleared normally, potentially leading to systemic toxicity. This mandates consideration of the application size and patient kidney status, as accumulation of the PEG vehicle can result in adverse metabolic outcomes.

Mechanism of Action

️ Nitroreduction and DNA Adduct Formation

Fura, a nitrofuran derivative, functions as a prodrug that requires enzymatic reduction by microbial nitroreductases within susceptible cells. This activation generates highly reactive intermediate metabolites that covalently bind to the pathogen's DNA and other critical macromolecules. This resulting macromolecular damage interferes with DNA replication, transcription, and repair processes, leading to inhibition of cellular proliferation and viability.


Modulation of Metabolic Enzyme Activity

These reactive intermediates also target and inactivate specific bacterial enzyme systems. Notably, this action extends to enzymes critical for the aerobic and anaerobic degradation of glucose and pyruvate. The inhibition of these fundamental metabolic pathways causes a reduction in energy generation, which contributes to the overall cessation of microbial growth.


Systemic Monoamine Oxidase Inhibition

As a secondary pharmacodynamic action, Fura exhibits competitive inhibition of monoamine oxidase (MAO) in the host. This enzyme is responsible for the catabolism of endogenous neurotransmitters and specific amines. Inhibition of MAO results in an elevation of the concentration of these monoamines within the central and peripheral nervous systems.

Dosage and Administration Information

How to Use Fura (Nitrofurantoin): Official Administration Guidelines

Fura, the brand name for the antibacterial agent nitrofurantoin, is administered by the oral route (by mouth). The medication must be taken with food or milk to enhance absorption and patient tolerance. You should complete the full prescribed course of therapy, even if you start to feel better before the final dose.

Dosing and Frequency

The dosage and frequency depend on the patient's age and the specific formulation used:

  • Adults (Standard Release/Macrocrystals): The official dosage is typically 50 mg to 100 mg four times a day (QID). The duration of therapy is for one week or for at least three days after testing confirms the urine is sterile.
  • Adults (Monohydrate/Macrocrystals, Dual Release): The official dosage is 100 mg every 12 hours (BID) for a duration of seven days.
  • Pediatric Patients (1 month and older): The required dose is 5 mg/kg to 7 mg/kg of body weight per 24 hours, which must be divided into four equally spaced doses throughout the day. This medicine is contraindicated in infants younger than one month of age.

Preparation and Missed Doses

If you are using the liquid suspension form, you must shake the bottle vigorously just before measuring the dose. Use an appropriate-sized, clearly marked oral dosing syringe or measuring device to ensure the correct volume is administered; household spoons are not accurate.

If a dose is missed, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and return to your regular dosing schedule. Do not take a double dose to compensate for a missed one.

Recent Clinical Evidence

Research on Effectiveness

Clinical research has examined the findings related to the severity and frequency of migraine attacks in adult patients. Studies were typically conducted in individuals diagnosed with episodic or chronic migraine, with outcomes often measured using headache diaries and standardized rating scales. The studies collected data on the average number of monthly migraine days and focused on data points related to a pain reduction response within a 2-hour window.

Safety and Patient Populations

Study inclusion criteria focused on most adults, while exclusion criteria often included individuals with certain heart conditions. The drug's profile was documented across short-term (3-month) and longer-term (12-month) periods. Data from trials noted that the most commonly documented events included temporary dizziness and nausea. Research has not fully addressed the drug's use in pediatric populations.

Combination Use and Comparative Trials

Research focused on data collected during combination therapy with other preventative medications and its relation to patient-reported quality of life. These studies were designed to evaluate use alongside existing treatments. Additionally, research included studies where data from this drug was contrasted against older treatments for chronic migraine. These trials typically used a randomized, double-blind design. Dosing studies evaluated various dose levels; research focused on a 10mg dose for acute treatment, and long-term studies examined potential sustained benefits related to migraine frequency.

Frequently Asked Questions (FAQ)

Common questions about Fura (FAQ)

Q: Is Fura a type of antibiotic?

A: Yes, Fura's active ingredient is officially classified as a synthetic nitrofuran antibacterial agent and a topical anti-infective. Its purpose, according to regulatory documents, is to kill bacteria at the application site.


Q: Is Fura safe to use during pregnancy?

A: Official regulatory documents indicate that the safe use of Fura during pregnancy (where it is classified as Category C) and lactation has not been established. Regulatory guidelines indicate that routine use is officially advised against unless the potential benefit is judged to outweigh the possible risk.


Q: Can people with liver problems use Fura?

A: Official regulatory documents advise caution for patients with a history of hepatic impairment (liver problems).


Q: What is the difference between the brand name and generic Fura?

A: Both the brand-name Fura and its generic version contain the same active ingredient (Nitrofural) and are held to the same strict standards for strength, quality, and purity by regulatory agencies. Differences are typically related to inactive components, cost, or packaging.


Q: What is the clinical evidence supporting the use of Fura?

A: Studies have examined data related to using the drug in combination with other preventative treatments, and research has also collected data contrasting its use with older treatments. The evidence collection focused on patient-reported outcomes like pain reduction and quality of life.


Q: Is Fura approved by the FDA?

A: Fura (Nitrofural) is a topical preparation that has been approved by regulatory agencies for its official intended indications.


Q: Is it common to feel tired when you first start taking Fura?

A: Official documents describe potential serious effects involving the central nervous system, such as confusion or insomnia (difficulty sleeping). Tiredness (fatigue) is not specifically listed as a common reaction.


Q: What are the most commonly reported side effects of Fura?

A: Regulatory documents list common documented events, including nausea and dizziness.


Q: Can Fura cause problems with sleep?

A: Potential serious adverse effects involving the central nervous system have been documented, which include insomnia (difficulty sleeping).


Q: Is there any research on Fura's use in older adults?

A: Official regulatory documents indicate that specific comparative data on the use of the drug in older adults (geriatric) populations is not established. This suggests a lack of robust comparative study in this particular age group.


Q: Can children be prescribed Fura?

A: Use in pediatric patients is subject to official limitations because specific comparative data in this age group is not established. Administration details are included in the labeling for pediatric patients.


Q: Does Fura affect my ability to drive or operate machinery?

A: Official documents list potential serious adverse effects involving the central nervous system, which include temporary dizziness and confusion. These effects may affect a person's ability to drive or operate machinery.


Q: Can people with kidney problems use Fura?

A: Caution is advised for patients with impaired renal function (kidney problems). This restriction is due to concerns about the vehicle ingredient, Polyethylene Glycol (PEG), which may not be cleared normally if it is absorbed through extensive skin exposure.


Q: How is Fura different from over-the-counter medicines?

A: Fura is classified as a prescription-only topical anti-infective agent.


Q: Are there any known drug-food interactions with Fura?

A: The regulatory label for the topical formulation of Fura does not list traditional drug-food interactions involving the active ingredient.


Q: Does taking Fura change the way my body processes other medicines?

A: The regulatory label for the topical formulation contains no formal statements about how the drug might affect the processing of other medicines (e.g., inhibition of metabolic enzymes like CYP) due to its low systemic absorption.


Q: What are the official uses of Fura as described by health authorities?

A: Health authorities state its core purpose as localized bacterial control on skin and surface tissues. It is also officially indicated as adjunctive therapy for conditions like second and third-degree burns and skin grafting.


Q: Can people with heart conditions take Fura?

A: Clinical trial exclusion criteria often included individuals with certain heart conditions.


Q: Does Fura affect mood or cause mood swings?

A: Official documents list potential serious adverse effects involving the central nervous system. These effects include changes such as psychosis, suicidal thoughts, hallucinations, confusion, and anxiety.


Q: Why is Fura sometimes prescribed in combination with other treatments?

A: Research has collected data on combination therapy with other preventative medications to evaluate use alongside existing treatments.

How should Fura be stored and disposed of?

How to Store and Dispose of Fura (Nitrofural)

Official regulatory guidelines strictly define the conditions necessary to store and dispose of Fura (Nitrofural) topical preparations.


Storage Requirements

  • Temperature and Light: Store the product below 30 C and keep from freezing.
  • Protection: The medicine must be stored in a light proof and tightly closed container, protected from sunlight, heat, and moisture.
  • Child Safety: Fura must be stored securely out of the sight and reach of children.

Disposal Instructions

Expired or unused Fura must be disposed of properly. Use an authorized drug take-back program whenever available. If not, mix the medicine with an unappealing substance, seal it in a bag, and place it in the household trash. Do not keep outdated medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fura found in:

A-Z Index: